116 related articles for article (PubMed ID: 16770110)
41. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
[TBL] [Abstract][Full Text] [Related]
42. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
43. New progress in treatment of hormone-refractory prostate cancer.
Ahmad K
Lancet Oncol; 2004 Dec; 5(12):706. PubMed ID: 15599999
[No Abstract] [Full Text] [Related]
44. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Di Lorenzo G; Figg WD; Fossa SD; Mirone V; Autorino R; Longo N; Imbimbo C; Perdonà S; Giordano A; Giuliano M; Labianca R; De Placido S
Eur Urol; 2008 Nov; 54(5):1089-94. PubMed ID: 18276061
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
46. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Petrioli R; Paolelli L; Francini E; Manganelli A; Salvestrini F; Francini G
Urology; 2007 Jan; 69(1):142-6. PubMed ID: 17270637
[TBL] [Abstract][Full Text] [Related]
47. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
48. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
49. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
50. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
51. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
52. [Optimal treatment for elderly high-risk prostate cancer patients].
Soga N; Sugimura Y
Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
[TBL] [Abstract][Full Text] [Related]
53. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
54. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract][Full Text] [Related]
55. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
56. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
[TBL] [Abstract][Full Text] [Related]
57. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
58. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
59. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
Wolff JM
Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
[TBL] [Abstract][Full Text] [Related]
60. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]